Adaptimmune Sells Four Core Cell TherapiesAdaptimmune
BiotechAdaptimmune Therapeutics sells four core cell therapies to US WorldMeds for $85M, ensuring continued patient access and advancing development of TECELRA, Lete-Cel, Afami-Cel, and Uza-Cel.
FDA Reconsiders Elevidys Amid Safety ConcernsFDA
SareptaThe FDA is reevaluating Sarepta's gene therapy Elevidys after a third patient death linked to its treatments. The agency may halt shipments amid rising safety concerns and market fallout.
GSK and Bharat Biotech to Cut Malaria Vaccine CostGSK
VaccineGSK and Bharat Biotech plan to reduce the cost of Mosquirix, the world’s first WHO-approved malaria vaccine, to under $5 per dose by 2028, aiming to expand global access and support Gavi’s child immunization goals across Africa.
Sanofi and Gilead Expand Protein Degrader PortfoliosSanofi
GileadSanofi and Gilead deepen their partnerships with Kymera Therapeutics, focusing on next-gen protein degraders for cancer and immune diseases in multi-million dollar deals, signaling rising industry interest.
GSK Strengthens Blenrep's Case with New DataGSK
EHAGSK’s Blenrep demonstrates significant progression-free survival improvements in multiple myeloma trials DREAMM-8 and DREAMM-7, strengthening its case for a U.S. market return with FDA decision expected by July 2025.
